Pantoprazole Actavis (Pantoprazole Sodium)

Pantoprazole, the active ingredient in Pantoprazole Actavis, is a proton pump inhibitor presented as an oral tablet for gastroenteral use. It reduces gastric acid secretion and is employed to treat conditions such as gastro‑oesophageal reflux disease, erosive esophagitis and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Pantoprazole Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Pantoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of the esophageal lining. - Erosive esophagitis: decreases gastric acid exposure, allowing ulcerated esophageal tissue to heal. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Pantoprazole may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Severe allergic reactions: including anaphylaxis, angioedema or Stevens‑Johnson syndrome. - Clostridioides difficile infection: risk of severe colitis. - Hypomagnesemia: low blood magnesium levels, potentially causing muscle cramps or arrhythmias. - Bone fractures: increased risk with long‑term use, especially in the hip, wrist or spine.

When prescribing Pantoprazole, clinicians should consider several precautionary measures to ensure safe use. - Renal function assessment: adjust use in patients with severe renal impairment. - Hepatic impairment: use with caution in moderate to severe liver disease. - Long‑term therapy monitoring: evaluate risk of osteoporosis‑related fractures. - Discontinuation strategy: avoid abrupt cessation after prolonged use; taper if needed. - Concomitant medication review: assess for drugs that may interact or require dose adjustment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, leading to subtherapeutic antiviral levels. - HIV protease inhibitors (e.g., ritonavir): lowered plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring more frequent monitoring. - Digoxin: increased serum levels, risk of toxicity. - Methotrexate: elevated concentrations, especially at high doses.